SCI faculty member's genome engineering technology attracts funding for start-up company
December 16, 2020
SCI member Branden Moriarity, PhD, Assistant Professor of Pediatrics at the University of Minnesota Medical School, has developed genome engineering technology that enables natural killer (NK) cells to be efficiently engineered as an “off the shelf” customizable cell therapy to treat solid tumor cancers. Moriarty is one of two scientific founders of Boston-based Catamaran Bio, which is the first UMN startup to attract funding from a top-tier venture capital firm. Learn more.